Centre de Référence Maladies Rares


Biotherapy of genetic diseases, inflammatory disorders and cancers (BMGIC)

FR: Biologie Fondamentale Appliquée à la Médecine

U1035Display navigation INSERM U1035! FR / EN

Christophe GROSSET

INSERM Research Directorhead of MiRCaDe team, christophe.grosset@u-bordeaux.fr



Study the molecular processes, genes and microRNAs involved in liver cancer in adults (hepatocellular carcinoma) and children (hepatoblastoma).


1. Grosset, C, CY Chen, N Xu, N Sonenberg, H Jacquemin-Sablon, and AB Shyu, A mechanism for translationally coupled mRNA turnover: interaction between the poly(A) tail and a c-fos RNA coding determinant via a protein complex. Cell, 2000. 103(1): p. 29-40.
2. Solanilla, A, C Grosset, C Lemercier, M Dupouy, FX Mahon, K Schweitzer, J Reiffers, B Weksler, and J Ripoche, Expression of Flt3-ligand by the endothelial cell. Leukemia, 2000. 14(1): p. 153-62.
3. Harizi, H, M Juzan, C Grosset, M Rashedi, and N Gualde, Dendritic cells issued in vitro from bone marrow produce PGE that contributes to the immunomodulation induced by antigen-presenting cells. Cell Immunol, 2001. 209(1): p. 19-28.
4. Grosset, C, R Boniface, P Duchez, A Solanilla, B Cosson, and J Ripoche, In vivo studies of translational repression mediated by the granulocyte-macrophage colony-stimulating factor AU-rich element. J Biol Chem, 2004. 279(14): p. 13354-62.
5. Solanilla, A, JM Pasquet, JF Viallard, C Contin, C Grosset, J Dechanet-Merville, M Dupouy, M Landry, F Belloc, P Nurden, P Blanco, JF Moreau, JL Pellegrin, AT Nurden, and J Ripoche, Platelet-associated CD154 in immune thrombocytopenic purpura. Blood, 2005. 105(1): p. 215-8.
6. Sagliocco, F, B Laloo, B Cosson, L Laborde, M Castroviejo, J Rosenbaum, J Ripoche, and C Grosset, The ARE-associated factor AUF1 binds poly(A) in vitro in competition with PABP. Biochem J, 2006. 400(2): p. 337-47.
7. Laloo, B, D Simon, V Veillat, D Lauzel, V Guyonnet-Duperat, F Moreau-Gaudry, F Sagliocco, and C Grosset, Analysis of post-transcriptional regulations by a functional, integrated, and quantitative method. Mol Cell Proteomics, 2009. 8(8): p. 1777-88.
8. Simon, D, B Laloo, M Barillot, T Barnetche, C Blanchard, C Rooryck, M Marche, I Burgelin, I Coupry, N Chassaing, B Gilbert-Dussardier, D Lacombe, C Grosset, and B Arveiler, A mutation in the 3’-UTR of the HDAC6 gene abolishing the post-transcriptional regulation mediated by hsa-miR-433 is linked to a new form of dominant X-linked chondrodysplasia. Hum Mol Genet, 2010. 19(10): p. 2015-27.
9. Jalvy-Delvaille, S., M. Maurel, V. Majo, N. Pierre, S. Chabas, C. Combe, J. Rosenbaum, F. Sagliocco, and C.F. Grosset, Molecular basis of differential target regulation by miR-96 and miR-182: the Glypican-3 as a model. Nucleic Acids Res, 2012. 40(3): p. 1356-65.
10. Maurel, M., S. Jalvy, Y. Ladeiro, C. Combe, L. Vachet, F. Sagliocco, P. Bioulac-Sage, V. Pitard, H. Jacquemin-Sablon, J. Zucman-Rossi, B. Laloo, and C.F. Grosset, A functional screening identifies five microRNAs controlling glypican-3: role of miR-1271 down-regulation in hepatocellular carcinoma. Hepatology, 2013. 57(1): p. 195-204.
11. Maurel, M., Dejeans, N., Taouji, S., Chevet, E. and C.F. Grosset. MicroRNA-1291-mediated silencing of IRE1alpha enhances Glypican-3 expression. RNA, 2013. 19, 778-788.
12. Indersie, E, S Lesjean, KB Hooks, F Sagliocco, T Ernault, S Cairo, M Merched-Sauvage, A Rullier, B Le Bail, S Taque, M Grotzer, S Branchereau, C Guettier, M Fabre, L Brugières, M Hagedorn, MA Buendia, and CF Grosset, MicroRNA therapy inhibits hepatoblastoma growth in vivo by targeting beta-catenin and Wnt signaling. Hepatology Communications, 2017. 1(2): p. 168-183.
13. Cartier F, Indersie E, Lesjean S, Charpentier J, Hooks KB, Ghousein A, Desplat A, Dugot-Senant N, Trezeguet V, Sagliocco F, Hagedorn M, Grosset CF. New tumor suppressor microRNAs target glypican-3 in human liver cancer. Oncotarget 2017;8(25):41211-26. doi: 10.18632/oncotarget.17162
14. Audoux, J, M Salson, CF Grosset, S Beaumeunier, JM Holder, T Commes, and N Philippe, SimBA: A methodology and tools for evaluating the performance of RNA-Seq bioinformatic pipelines. BMC Bioinformatics, 2017. 18(1): p. 428.
15. Hooks, KB, J Audoux, H Fazli, S Lesjean, T Ernault, N Dugot-Senant, T Leste-Lasserre, M Hagedorn, B Rousseau, C Danet, S Branchereau, L Brugières, S Taque, C Guettier, M Fabre, A Rullier, MA Buendia, T Commes, AA Raymond*, and CF Grosset *, New insights into diagnosis and therapeutic options for proliferative hepatoblastoma. Hepatology, accepté pour publication, 2017. * co-last authors.
16. Saad, A, B Liet, G Joucla, X Santarelli, J Charpentier, S Claverol, CF Grosset, and V Trézéguet, Role of O-glycanation and convertase maturation of the soluble Glypican-3 in inhibiting proliferation of hepatocellular carcinoma cells. Biochemistry, in press, 2018.
17. Indersie, E, KB Hooks, C Capdevielle, M Fabre, N Dugot-Senant, A Desplat, S Lepreux, A Merched, CF Grosset, and M Hagedorn, Tracking cellular and molecular changes in a species-specific manner during experimental hepatoblastoma progression in vivo. Oncotarget, in press, 2018.

Subventions et contrats :

- INCa, TRANSLA 2013, “Regulation of Wnt/beta-catenin signaling and MicroRNAs: application to the treatment of hepatoblastoma, a rare pediatric cancer”, 3 years, (Applicant and coordinator: C.F. Grosset), Collaborators: Marie-Annick Buendia, U785 INSERM, Villejuif, France; Sophie Taque, Rennes University Hospital, France; Laurence Brugières, Gustave Roussy Institute, Villejuif, France; Stefano Cairo, Xentech company, France; SIOPEL network.
- FRM, BIOINFO 2013, “Functional genomic studies of hepatoblastoma by RNA-seq as a source of new diagnostic biomarkers and therapeutic targets”, 3 years, (Applicant and coordinator: C.F. Grosset), Collaborators: Marie-Annick Buendia, U785 INSERM, Villejuif, France; Thérèse Commes, U1040 INSERM, Montpellier, France.
- INCa, PLBIO 2012, “Glypican-3 : therapeutic target in liver cancer treatment”, 3 years, (Applicant and coordinator: C.F. Grosset), Collaborators: Véronique Trézéguet, Michel Hugues et Bernard Gallois, CBMN UMR 5248, Pessac, France; Jessica Zucman-Rossi, U674 INSERM, Paris, France; Jorge Filmus, Sunnybrook Health Sciences Centre, Toronto, Canada.
- ANR, 2010, “Pathophysiologic role of HDAC6 overexpression consecutive to a mutation abrogating a miRNA-mediated post-transcriptional regulation in an X-linked chondrodysplasia”, 3 years, (Applicant: B. Arveiler)
- Others grants : Cancéropôle Grand Sud-Ouest, La Ligue Nationale contre le Cancer, the University of Bordeaux Excellence Initiative 2014 and 2016 Post-doctoral fellowship program, charity grants (ESCAPE, Eva pour la Vie, Aidons Marina, KAena et les Lapinours, Fondation Flavien, Cassandra contre la leucémie, TFEM, Fondation Groupama pour la Santé), Région Aquitaine.
- Aquitaine Science Transfer/MATWIN coaching : Grant for a maturation project aiming at supporting the transfer of a microRNA to the clinic for the treatment of liver cancer.


  • Use of Glypican-3-targeting microRNAs for treating liver cancer. EP 15 3061072 European patent UNIVERSITE DE BORDEAUX-INSERM
  • Use of catenin-beta 1-targeting microRNAs for treating liver cancer. EP 15 3061130 European patent UNIVERSITE DE BORDEAUX-INSERM-UNIVERSITE PARIS SUD - PARIS XI


Back to organigramme

INSERM U1035! - University of Bordeaux
146 rue Léo Saignat - PE building south zone, 4th floor
33000 Bordeaux
Work +33 557 57 13 73/74